20-21 September 2017 the conference Immuno-Oncology Frontiers will take place in Berlin, and Øystein Rekdal (Co-founder and CSO in Lytix Biopharma) will  present ‘Oncolytic peptides - a novel approach to make tumors more sensitive to immune checkpoint inhibitors’.

Rekdal’s main research focus has been oncolytic peptides and their abilities to induce potent tumor specific immune responses. Rekdal/Lytix Biopharma is currently collaborating with several distinguished researchers to further exploring the unique ability of oncolytic peptides to generate an immunogenic tumor microenvironment. 

Read more about the conference here.